Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo.
about
Gene therapy for skin diseasesOne goal, different strategies--molecular and cellular approaches for the treatment of inherited skin fragility disordersAminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa.Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrityInduced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.Downregulation of endothelial microRNA-200b supports cutaneous wound angiogenesis by desilencing GATA binding protein 2 and vascular endothelial growth factor receptor 2Bone marrow transplantation for recessive dystrophic epidermolysis bullosaEfficient in vivo targeting of epidermal stem cells by early gestational intraamniotic injection of lentiviral vector driven by the keratin 5 promoter.Downregulation of TNIP1 Expression Leads to Increased Proliferation of Human Keratinocytes and Severer Psoriasis-Like Conditions in an Imiquimod-Induced Mouse Model of DermatitisGene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.Gene therapy in combination with tissue engineering to treat epidermolysis bullosa.A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.Gene therapy progress and prospects: the skin--easily accessible, but still far away.Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB.Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cellsKeratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation.Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.Lentiviral vectors for cutaneous RNA managing.Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa.Characterization of factors that determine lentiviral vector tropism in skin tissue using an ex vivo model.A knot polymer mediated non-viral gene transfection for skin cells.SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure.Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosaLong-term type VII collagen restoration to human epidermolysis bullosa skin tissue.Lentivirus shRNA Grb10 targeting the pancreas induces apoptosis and improved glucose tolerance due to decreased plasma glucagon levels.Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patientsThermosensitive hydrogel for prolonged delivery of lentiviral vector expressing neurotrophin-3 in vitro.CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls.
P2860
Q26994703-1510DF2B-F11F-4768-87BD-4DDE085F44A7Q27026711-72C9D22E-6D9A-4256-8C98-CE163E0CB35BQ30650123-A0635131-4C3D-4D8E-AF26-2BE199BB52A6Q33712943-ABA9C530-95D8-434A-A190-3FBE4B59B2C7Q33713926-83218BEA-688A-4660-88D3-EE0B3207B28EQ34120479-1F291118-83DE-4F96-A025-D9DCF9924A31Q34231577-AF686068-70CE-4EF1-BFE9-F886043EA7DDQ34256616-380C1BA7-F1FB-40AD-8628-E19D4765CDC2Q35138244-9E5A20B9-9E04-4216-98DF-FF0E5342EACFQ35653856-9E5DD741-7DCB-4C71-B007-3D0138E7548DQ36326838-4735B6A4-A8BA-44EE-B9D9-87A54223E347Q36425931-A21EEF30-98D2-431E-B3CA-87436FED8D0FQ36512219-9FCD2548-3B62-4989-A1EA-BD577A68A093Q36587586-D3A1E091-92AF-47D6-8852-E64EBF8A25F1Q36595683-0E803DAB-22DB-4EDD-9338-1B94326DC327Q37082009-7FE851D0-A5E1-4D14-BFD0-B6AC66C2AED8Q37462643-DDC262FF-7FD9-42D6-92A9-2F607B63794EQ37649276-A07FA3CC-FBBD-4203-8960-24ABAEEDB56FQ37712686-7A7906C9-367A-4D64-8E58-8565BECEE07EQ37989486-2792C970-4E93-46D1-A534-D3E6EF368502Q38150897-FE6B44FA-CDA9-462D-931C-DE9AB4E567C9Q38379970-83C20590-0DEA-4CF0-81A5-E5394B8AD3C5Q39574263-5A73ABE2-205A-42E1-897B-99838E15DD92Q41361651-27659678-101C-47CA-82A2-FB80BB4C3E5BQ41811020-CEB85490-BD6D-43F9-99BF-3E14CCF93FDBQ41815771-ED3943FE-4BEB-4D1B-B09F-1009A6DA7346Q41868932-C5C0CCEC-25EC-41E7-BBFE-048F8B369622Q41956259-A5C375E4-76CB-4D94-9C8F-3B2271FBB986Q42500046-7619D2CB-A937-49EE-86DE-90094C287F25Q42644106-E68D4A42-FDBA-4FF9-94A5-6E157EB878CBQ50511147-D80F5C03-6F7E-42B3-9816-7A1C6B79601DQ50897287-F3712234-FF8E-4945-856C-8A61F02D253FQ53143040-ABCD1BBA-EF87-4375-BE72-1659F1C5FFCC
P2860
Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Intradermal injection of lenti ...... s bullosa skin tissue in vivo.
@en
Intradermal injection of lenti ...... s bullosa skin tissue in vivo.
@nl
type
label
Intradermal injection of lenti ...... s bullosa skin tissue in vivo.
@en
Intradermal injection of lenti ...... s bullosa skin tissue in vivo.
@nl
prefLabel
Intradermal injection of lenti ...... s bullosa skin tissue in vivo.
@en
Intradermal injection of lenti ...... s bullosa skin tissue in vivo.
@nl
P2093
P1433
P1476
Intradermal injection of lenti ...... s bullosa skin tissue in vivo.
@en
P2093
David T Woodley
Douglas R Keene
Noriyuki Kasahara
P304
P356
10.1016/J.YMTHE.2004.05.016
P577
2004-08-01T00:00:00Z